There are currently 196 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
NCT05135351
Recruiting
Higher gut microbiome diversity has been associated with improved survival following autologous stem cell transplantation in multiple myeloma and lymphoma. This study hypothesises that prebiotic supplementation with resistant starch (RS) will improve gut microbiome diversity at time of stem cell engraftment. To test this, participants will either have RS or a placebo (maltodextrin) mixed into a food item of their choice for approximately 10 days prior to stem cell infusion and continue to the fi... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
06/14/2024
Locations: Unversity of Nebraska Medical Center, Omaha, Nebraska
Conditions: Multiple Myeloma, Lymphoma
Register for Updates
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT06179888
Recruiting
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California +3 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +119 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
NCT04268498
Recruiting
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: University of Miami, Miami, Florida +8 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054
Recruiting
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evid... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan +32 locations
Conditions: Multiple Myeloma
Register for Updates
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535
Recruiting
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). **************************... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
06/10/2024
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +160 locations
Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Register for Updates
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
NCT01890486
Recruiting
To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/10/2024
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Germ Cell Neoplasms, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immunodeficiency Diseases
Register for Updates
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
NCT05673083
Recruiting
The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: • Does All4Cure effect patient activation as assessed by the PAM-13 survey? Participants will be asked to: fill out quarterly PAM-13 surveys through the All4Cure website to assess patient activation. fill out monthly Patient Reported Outcome (PRO) surveys through the All4Cure website. fill out a baseline and exit All4Cure surveys through the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Highlands Oncology Group, Fayetteville, Arkansas +4 locations
Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
Register for Updates
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
NCT05828511
Recruiting
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: University of California, Los Angeles, California +9 locations
Conditions: Multiple Myeloma
Register for Updates
Collection of Tissue Samples for Cancer Research
NCT00900198
Recruiting
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. To obtain samples for re... Read More
Gender:
All
Ages:
2 months and above
Trial Updated:
06/06/2024
Locations: UC Davis, Sacramento, California +16 locations
Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
Register for Updates
Two Implementation Strategies for the Collection of Electronic Patient-Reported Outcomes Among Patients With Multiple Myeloma
NCT06041698
Recruiting
This clinical trial evaluates satisfaction and engagement with a text messaging platform (TXT-Chatbot) compared to a patient portal system (MyChart/Patient Portal) for reporting symptoms among patients with multiple myeloma (MM). Multiple myeloma is the third most common hematologic (relating to the blood and blood-forming organs) cancer. Patients with MM typically receive continuous therapy from the time of diagnosis, which often comes with treatment-related toxicities. Symptom burden and healt... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Multiple Myeloma
Register for Updates
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
NCT02356159
Recruiting
Background: - In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient s immune system destroys the donor s cells. Or donor immune cells attack the recipient s tissues, called graft-versus-host disease (GVHD). This is less likely when the recipient and donor have similar human leukocyte antigens (HLA). Researchers want to see if the drug palifermin improves the results of allogeneic SCT from HLA-matched unrelated donors.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Register for Updates